pentoxifylline has been researched along with Weight Gain in 6 studies
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline (PTX) is a drug shown to have beneficial anti-inflammatory effects in cancer patients, mainly through anti-TNFα mechanisms." | 3.11 | PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics. ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2022) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "His disease relapsed without recurrence of the capillary leak." | 1.31 | Systemic capillary leak syndrome preceding plasma cell leukaemia. ( Ghosh, K; Iyer, Y; Jijina, F; Madkaikar, M; Mohanty, D; Pathare, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Meirovitz, A | 2 |
| Baider, L | 2 |
| Peretz, T | 2 |
| Stephanos, S | 2 |
| Barak, V | 2 |
| Andrade, Wde C | 1 |
| Tannuri, U | 1 |
| da Silva, LF | 1 |
| Alves, VA | 1 |
| Striffler, JS | 1 |
| Nadler, JL | 1 |
| Frantz, RP | 1 |
| Edwards, BS | 1 |
| Olson, LJ | 1 |
| Schwab, MK | 1 |
| Adams, TF | 1 |
| Textor, SC | 1 |
| Daly, RC | 1 |
| McGregor, CG | 1 |
| Rodeheffer, RJ | 1 |
| Ghosh, K | 1 |
| Madkaikar, M | 1 |
| Iyer, Y | 1 |
| Pathare, A | 1 |
| Jijina, F | 1 |
| Mohanty, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
3 trials available for pentoxifylline and Weight Gain
| Article | Year |
|---|---|
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics.
Topics: Anti-Inflammatory Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Colonic Neoplasms; Cytokines; | 2022 |
Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Weight; Cyclosporine; Doubl | 1997 |
3 other studies available for pentoxifylline and Weight Gain
| Article | Year |
|---|---|
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals.
Topics: Animals; Biliary Atresia; Biliary Tract Diseases; Cholestasis; Common Bile Duct Diseases; Disease Mo | 2009 |
Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Diabetes Mellitus, Experimental; Ea | 2004 |
Systemic capillary leak syndrome preceding plasma cell leukaemia.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capillar | 2001 |